RAND Corporation From the SelectedWorks of Emmett Keeler March , 1995 The Cost Effectiveness of Preoperative Autologous Blood Donations
暂无分享,去创建一个
E. Keeler | R. Brook | S. Kleinman | J. Etchason | L. Petz | A. Fink | C. Snider | C. Snider | L. Calhoun | R. Brook | Arlene Fink
[1] E. L. Wallace,et al. Collection and transfusion of blood and blood components in the United States, 1992 , 1995, Transfusion.
[2] L. Goodnough. The implications of cost-effectiveness for autologous blood procurement. , 1994, Archives of pathology & laboratory medicine.
[3] K. Friedman,et al. On improving the cost‐effectiveness of autologous blood transfusion practices , 1994, Transfusion.
[4] J. Birkmeyer,et al. Cost-effectiveness of preoperative autologous donation in coronary artery bypass grafting. , 1994, The Annals of thoracic surgery.
[5] F. Schildberg,et al. Beneficial effect of autologous blood transfusion on infectious complications after colorectal cancer surgery , 1993, The Lancet.
[6] F J Hellinger,et al. The lifetime cost of treating a person with HIV. , 1993, JAMA.
[7] P D Cleary,et al. Health-Related Quality of Life in Persons with Acquired Immune Deficiency Syndrome , 1993, Medical care.
[8] J. Birkmeyer,et al. The cost‐effectiveness of preoperative autologous blood donation for total hip and knee replacement , 1993, Transfusion.
[9] B. Bloom,et al. A Reappraisal of Hepatitis B Virus Vaccination Strategies Using Cost-Effectiveness Analysis , 1993, Annals of Internal Medicine.
[10] E. L. Wallace,et al. Collection and transfusion of blood and blood components in the United States, 1989 , 1993, Transfusion.
[11] F. Iber,et al. Long-Term Mortality after Transfusion-Associated Non-A, Non-B Hepatitis , 1992 .
[12] D. Smith. Immunosuppressive effects of blood transfusion. , 1992, Clinics in laboratory medicine.
[13] A. Muñoz,et al. Transmission of Retroviruses from Seronegative Donors by Transfusion during Cardiac Surgery , 1992, Annals of Internal Medicine.
[14] J. Barber,et al. Autologous-blood transfusion: the reimbursement dilemma. , 1992, The Journal of bone and joint surgery. American volume.
[15] A. Muñoz,et al. The declining risk of post-transfusion hepatitis C virus infection. , 1992, The New England journal of medicine.
[16] R. Dodd. The risk of transfusion-transmitted infection. , 1992, The New England journal of medicine.
[17] P. J. Howanitz,et al. Preoperative autologous blood donation in 612 hospitals. A College of American Pathologists' Q-Probes study of quality issues in transfusion practice. , 1992, Archives of pathology & laboratory medicine.
[18] P. Toy. Continuous quality improvement. Autologous blood donations. , 1992, Archives of pathology & laboratory medicine.
[19] M. Popovsky. Autologous blood transfusion in the 1990s. Where is it heading? , 1992, American journal of clinical pathology.
[20] J. Fleishman,et al. Quality of Life in Persons with Human Immunodeficiency Virus Infection: Measurement by the Medical Outcomes Study Instrument , 1992, Annals of Internal Medicine.
[21] P. Tartter,et al. Postoperative infections following autologous and homologous blood transfusions , 1992, Transfusion.
[22] F. Sonnenberg,et al. The risks of blood transfusion: The relative influence of acquired immunodeficiency syndrome and non-A, non-B hepatitis , 1992 .
[23] G. Hicks,et al. Homologous blood transfusion as a risk factor for postoperative infection after coronary artery bypass graft operations. , 1992, The Journal of thoracic and cardiovascular surgery.
[24] D. Huestis,et al. An autologous blood program coordinated by a regional blood center: a 5‐ year experience , 1991, Transfusion.
[25] Alexander Jw. Transfusion‐induced immunomodulation and infection , 1991 .
[26] N. Blumberg,et al. Infection or suspected infection after hip replacement surgery with autologous or homologous blood transfusions , 1991, Transfusion.
[27] D. Triulzi,et al. Transfusion-induced immunomodulation and its clinical consequences. , 1990, Transfusion medicine reviews.
[28] K. Sazama,et al. Reports of 355 transfusion‐associated deaths: 1976 through 1985 , 1990, Transfusion.
[29] N. Blumberg,et al. Transfusion-induced immunomodulation and its possible role in cancer recurrence and perioperative bacterial infection. , 1990, The Yale journal of biology and medicine.
[30] J. Macpherson,et al. Markers for transfusion-transmitted disease in different groups of blood donors. , 1989, JAMA.
[31] P D Cumming,et al. Exposure of patients to human immunodeficiency virus through the transfusion of blood components that test antibody-negative. , 1989, The New England journal of medicine.
[32] G. Rutherford,et al. The natural history of transfusion-associated infection with human immunodeficiency virus. Factors influencing the rate of progression to disease. , 1989, The New England journal of medicine.
[33] D. Goldfinger,et al. Establishment of a schedule of optimal preoperative collection of autologous blood , 1989, Transfusion.
[34] R M Kaplan,et al. The Quality of Well-Being Scale: Applications in AIDS, Cystic Fibrosis, and Arthritis , 1989, Medical care.
[35] T. Simon,et al. The issues in autologous transfusion. , 1989, Human pathology.
[36] A. Grindon,et al. Increased risk of a positive test for antibody to hepatitis B core antigen (anti‐HBC) in autologous blood donors , 1988, Transfusion.
[37] E. E. Glazer,et al. Utilization and effectiveness of a hospital autologous preoperative blood donor program , 1986, Transfusion.
[38] E. Keeler,et al. Discounting of Life-Saving and Other Nonmonetary Effects , 1983 .
[39] G. Torrance,et al. The utility of different health states as perceived by the general public. , 1978, Journal of chronic diseases.
[40] M. Weinstein,et al. Foundations of cost-effectiveness analysis for health and medical practices. , 1977, The New England journal of medicine.
[41] collection and , 2022 .